Tag: tocilizumab_aazg

Fresenius Kabi Recalls Tyenne® Injection Vials Due to Glass Particles

12 Aug 2026 4:47 p.m. · Source: US Food and Drug Administration

Fresenius Kabi is recalling Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL vials nationwide due to glass particles, posing risks including blood clots and organ damage. The affected lot was shipped between March 3 and March 25, 2026.

Health Business Medical Science Legal Economy Product Recall Pharmaceuticals Fresenius Kabi Tyenne Tocilizumab-aazg Glass Particles Drug Safety Food Recalls FDA Drugs